Ladenburg Thalmann Downgrades Neovasc (NVCN) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Nasdaq, S&P dip, trading choppy as tech stocks fall
- Brent hits lowest since before start of Iran war as more tankers exit Hormuz, easing supply
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- JPMorgan raises S&P 500 target to 7,800, says earnings revision ’unprecedented’
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- UBS Reiterates Buy Rating on Snowflake Inc. (SNOW)
Neovasc Announces Jury Verdict in Litigation Brought by CardiAQ
May 19, 2016 7:28 PM EDTNASDAQ: NVCNTSX: NVC
VANCOUVER, May 19, 2016 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN) (TSX: NVC) today announced that following a trial in Boston, Massachusetts a jury found in favor of CardiAQ, on CardiAQ's claims for relief for breach of contract, breach of the duty of honesty in contractual performance, and three of CardiAQ's six asserted trade secrets. The jury also issued advisory findings in favor of CardiAQ regarding its causes of action under Massachusetts... More
